The Myth of Measurable Disease in Ovarian Cancer
- 15 August 2003
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (16) , 3013-3015
- https://doi.org/10.1200/jco.2003.08.148
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Declining CA-125 in an Ovarian Cancer Patient with Progression of Measurable Disease: A Rational Hypothesis for Discordant ResultsGynecologic Oncology, 2000
- Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II TrialsJournal of Clinical Oncology, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Comparison of Standard and CA-125 Response Criteria in Patients With Epithelial Ovarian Cancer Treated With Platinum or PaclitaxelJournal of Clinical Oncology, 1999
- Analysis of interobserver and intraobserver variability in CT tumor measurements.American Journal of Roentgenology, 1996
- CA 125: A valid marker in ovarian carcinoma patients treated with paclitaxel?Cancer, 1996
- Docetaxel in advanced ovarian cancer: Preliminary results from three phase II trialsEuropean Journal Of Cancer, 1995
- Reproducibility of Tumor Measurements in Ovarian Cancer: A Study of Interobserver VariabilityGynecologic Oncology, 1994
- Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.Journal of Clinical Oncology, 1984
- Reporting results of cancer treatmentCancer, 1981